Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4290-4296

  Chen, Chin Ming ^a   He, Yupeng ^a   Lu, Liangjun ^a   Lim, Hock Ben ^a   Tripathi, Rakesh L ^a   Middleton, Tim ^a   Hernandez, Lisa E ^a   Beno, David W A ^a   Long, Michelle A ^a   Kati, Warren M ^a   Bosse, Todd D ^a   Larson, Daniel P ^a   Wagner, Rolf ^a   Lanford, Robert E ^b   Kohlbrenner, William E ^a   Kempf, Dale J ^a   Pilot Matias, Tami J ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 837093; ANTIVIRUS AGENT; CILUPREVIR; MACROGOL 400; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CHIMPANZEE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; PHENOTYPE; PLASMA HALF LIFE; PRIORITY JOURNAL; REPLICON; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; BENZOTHIADIAZINES; BIOLOGICAL AVAILABILITY; CYCLIC S-OXIDES; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENOTYPE; HAPLORHINI; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR STRUCTURE; PAN TROGLODYTES; PHENOTYPE; RATS; RNA REPLICASE; RNA, VIRAL; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 36749032212     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00723-07     Document Type: Article

References (28)

1. Bukh, J. 2004. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39:1469-1475.
2. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
3. Del Vecchio, A. M., and R. T. Sarisky. 2006. Small molecule and biologic inhibitors of hepatitis C virus: a symbiotic approach. Mini Rev. Med. Chem. 6:1263-1268.
4. Fargion, S., A. L. Fracanzani, and L. Valenti. 2004. Treatment choices for people infected with HCV. J. Antimicrob. Chemother. 53:708-712.
5. Kantor, R., and D. Katzenstein. 2004. Drug resistance in non-subtype B HIV-1. J. Clin. Virol. 29:152-159.
6. Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamnie, A. Tanuri, P. Phanuphak, J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
7. Koev, G., T. Dekhtyar, L. Han, P. Yan, T. I. Ng, C. T. Lin, H. Mo, and A. Molla. 2007. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antivir. Res. 73:78-83.
8. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
9. Lanford, R. E., C. Bigger, S. Bassett, and G. Klimpel. 2001. The chimpanzee model of hepatitis C virus infections. ILAR J. 42:117-126.
10. Lanford, R. E., B. Guerra, H. Lee, D. R. Averett, B. Pfeiffer, D. Chavez, L. Notvall, and C. Bigger. 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77:1092-1104.
11. Lanford, R. E., B. Guerra, C. B. Bigger, H. Lee, D. Chavez, and K. M. Brasky. 2007. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46:999-1008.
12. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
13. Lee, J. H., I. Y. Nam, and H. Myung. 2006. Nonstructural protein 5B of hepatitis C virus. Mol. Cells 21:330-336.
14. Lindenbach, B. D., P. Meuleman, A. Ploss, T. Vanwolleghem, A. J. Syder, J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-Roels, and C. M. Rice. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. USA 103:3805-3809.
15. Liu, Y., W. W. Jiang, J. Pratt, T. Rockway, K. Harris, S. Vasavanonda, R. Tripathi, R. Pithawalla, and W. M. Kati. 2006. Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. Biochemistry 45:11312-11323.
16. Lu, L., T. Dekhtyar, S. Masse, R. Pithawalla, P. Krishnan, W. He, T. Ng, G. Koev, K. Stewart, D. Larson, T. Bosse, R. Wagner, T. Pilot-Matias, H. Mo, and A. Molla. 2007. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antivir. Res. 76:93-97.
17. Lu, L., T. J. Pilot-Matias, K. D. Stewart, J. T. Randolph, R. Pithawalla, W. He, P. P. Huang, L. L. Klein, H. Mo, and A. Molla. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266.
18. Middleton, T., Y. He, T. Pilot-Matias, R. Tripathi, H. B. Lim, A. Roth, C.-M. Chen, G. Koev, T. Ng, P. Krishnan, R. Pithawalla, R. Mondal, T. Dekhtyar, L. Lu, H. Mo, W. M. Kati, and A. Molla. 2007. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J. Virol. Methods 145:137-145.
19. Mo, H., L. Lu, T. Pilot-Matias, R. Pithawalla, R. Mondal, S. Masse, T. Dekhtyar, T. Ng, G. Koev, V. Stoll, K. D. Stewart, J. Pratt, P. Donner, T. Rockway, C. Maring, and A. Molla. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49:4305-4314.
20. Molla, A., R. Wagner, L. Lu, Y. He, C.-M. Chen, G. Koev, S. Masse, Y. Cai, C. Klein, D. Beno, L. Hernandez, P. Krishnan, R. Pithawalla, T. Pilot-Matias, T. Middleton, R. Lanford, W. Kati, and D. Kempf. 2007. Characterization of pharmacokinetic/pharmacodynamic parameters for the novel HCV polymerase inhibitor A-848837, abstr. 620. Abstr. 42nd Annu. Meet. Eur. Assoc. Study Liver.
21. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
22. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. D. Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
23. Tomei, L., S. Altamura, L. Bartholomew, M. Bisbocci, C. Bailey, M. Bosserman, A. Cellucci, E. Forte, I. Incitti, L. Orsatti, U. Koch, R. De Francesco, D. B. Olsen, S. S. Carroll, and G. Migliaccio. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946.
24. Tong, X., R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B. A. Malcolm. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir. Res. 70:28-38.
25. Tripathi, R. L., P. Krishnan, Y. He, T. Middleton, T. Pilot-Matias, C. M. Chen, D. T. Lau, S. M. Lemon, H. Mo, W. Kati, and A. Molla. 2007. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antivir. Res. 73:40-49.
26. World Health Organization. October 2000, revised 2000, posting date. Hepatitis C. World Health Organization, Geneva, Switzerland.
27. Yi, M., and S. M. Lemon. 2004. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 78:7904-7915.
28. Yi, M., X. Tong, A. Skelton, R. Chase, T. Chen, A. Prongay, S. L. Bogen, A. K. Saksena, F. G. Njoroge, R. L. Veselenak, R. B. Pyles, N. Bourne, B. A. Malcolm, and S. M. Lemon. 2006. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem. 281:8205-8215.